Phase <scp>II</scp> study of durvalumab monotherapy in patients with previously treated microsatellite instability‐high/mismatch repair‐deficient or <scp> <i>POLE</i> </scp> ‐mutated metastatic or unresectable colorectal cancer-Reference-Cited by-同舟云学术

Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability‐high/mismatch repair‐deficient or POLE ‐mutated metastatic or unresectable colorectal cancer

Published:2022-03 Issue:12 Volume:150 Page:2038-2045
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Oh Chung Ryul¹²^ORCID,Kim Jeong Eun¹,Hong Yong Sang¹,Kim Sun Young¹^ORCID,Ahn Joong Bae³,Baek Ji Yeon⁴,Lee Myung‐Ah⁵,Kang Myoung Joo⁶,Cho Sang Hee⁷,Beom Seung‐Hoon³,Kim Tae Won¹

Affiliation:

1. Department of Oncology, Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea

2. Department of Internal Medicine, Chung‐Ang University Hospital Chung‐Ang University College of Medicine Seoul Republic of Korea

3. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center Yonsei University College of Medicine Seoul Republic of Korea

4. Center for Colorectal Cancer, Research Institute and Hospital National Cancer Center Goyang Republic of Korea

5. Department of Oncology, Seoul St Mary's Hospital The Catholic University of Korea Seoul Republic of Korea

6. Division of Oncology, Department of Internal Medicine, Inje University College of Medicine Haeundae Paik Hospital Busan Republic of Korea

7. Department of Hematology‐Oncology Chonnam National University Hospital Hwasun Republic of Korea

Funder

Korea Health Industry Development Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33966

Reference28 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung H;CA Cancer J Clin,2021

2. Predicting Risk of Recurrence After Colorectal Cancer Surgery in the United States: An Analysis of a Special Commission on Cancer National Study

3. Patterns of metastasis in colon and rectal cancer

4. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

5. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel targeting strategies on signaling pathways of colorectal cancer;Colorectal Cancer;2024

2. All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality;Clinical Kidney Journal;2023-11-28

3. Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?;Cancers;2023-10-28

4. Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review;Frontiers in Pharmacology;2023-06-28

5. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors;Journal for ImmunoTherapy of Cancer;2023-05